awmsg logo



vildagliptin (Galvus®)


Reference No. 1529

Publication date:
22/03/2013


Appraisal information

vildagliptin (Galvus®) 50 mg tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 18/03/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, vildagliptin (Galvus®) cannot be endorsed for use within NHS Wales for the treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control; or in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.
Statement of Advice (SOA)
Download